LETTERS FOR ISSUE ON
|
|
|
- Marlene Roberts
- 5 years ago
- Views:
Transcription
1 S FOR ISSUE ON BE NOC FOR EXPORT S. NO. NAME OF THE COMPANY REF. NO. TYPE OF 1. M/S. ACCUTEST RESEARCH MUMBAI M/S. ACCUTEST RESEARCH MUMBAI M/S. ACCUTEST RESEARCH MUMBAI M/S. ACCUTEST RESEARCH MUMBAI M/S. ACCUTEST RESEARCH MUMBAI M/S. ACCUTEST RESEARCH MUMBAI M/S. ACCUTEST RESEARCH MUMBAI M/S. ACCUTEST RESEARCH MUMBAI M/S. ACCUTEST RESEARCH MUMBAI M/S. AIZANT DRUG RESEARCH SOLUTIONS PVT. LTD., HYDERABAD CLARIFICATION CLARIFICATION APPROVAL APPROVAL TEST LICENCE TEST LICENCE AMENDMENT AMENDMENT AMENDMENT CLARIFICATION
2 11. M/S. AIZANT DRUG RESEARCH SOLUTIONS PVT. LTD., HYDERABAD M/S. AIZANT DRUG RESEARCH SOLUTIONS PVT. LTD., HYDERABAD M/S. ALEMBIC PHARMACEUTICALS LTD., VADODARA M/S. ALEMBIC PHARMACEUTICALS LTD., VADODARA M/S. ALEMBIC PHARMACEUTICALS LTD., VADODARA M/S. ALEMBIC PHARMACEUTICALS LTD., VADODARA M/S. ALKEM LABORATORIES LTD., DIST: RAIGAD 18. M/S. ALKEM LABORATORIES LTD., DIST: RAIGAD 19. M/S. APL RESEARCH CENTER, HYDERABAD M/S. APL RESEARCH CENTER, HYDERABAD M/S. APL RESEARCH CENTRE, AUROBINDO PHARMA LTD., HYDERABAD M/S. AXIS CLINICAL LTD., HYDERABAD M/S. AXIS CLINICALS LTD., HYDERABAD M/S. AZIDUS LABORATORIES LTD., CHENNAI M/S. AZIDUS LABORATORIES LTD., CHENNAI M/S. AZIDUS LABORATORIES LTD., CHENNAI CLARIFICATION CLARIFICATION CLARIFICATION CLARIFICATION CLARIFICATION AMENDMENT CLARIFICATION CLARIFICATION CLARIFICATION CLARIFICATION 6572 APPROVAL 6971 APPROVAL REJECTION CLARIFICATION CLARIFICATION CLARIFICATION
3 27. M/S. CIPLA LIMITED, MUMBAI M/S. CIPLA LIMITED, MUMBAI M/S. CIPLA LIMITED, MUMBAI M/S. CIPLA LIMITED, MUMBAI M/S. CIPLA LIMITED, MUMBAI M/S. CLIANTHA RESEARCH LIMITED, 33. M/S. CLIANTHA RESEARCH LIMITED, 34. M/S. CLIANTHA RESEARCH LIMITED, 35. M/S. CLIANTHA RESEARCH LIMITED, 36. M/S. CLIANTHA RESEARCH LIMITED, 37. M/S. CLIANTHA RESEARCH LIMITED, 38. M/S. CLIANTHA RESEARCH LIMITED, 39. M/S. CLIANTHA RESEARCH LIMITED, 40. M/S. CLIANTHA RESEARCH LIMITED, 41. M/S. CLIANTHA RESEARCH LIMITED, 42. M/S. CLIANTHA RESEARCH LIMITED, 43. M/S. CLIANTHA RESEARCH LIMITED, APPROVAL APPROVAL APPROVAL TEST LICENCE AMENDMENT CLARIFICATION CLARIFICATION CLARIFICATION CLARIFICATION CLARIFICATION CLARIFICATION CLARIFICATION CLARIFICATION CLARIFICATION CLARIFICATION CLARIFICATION CLARIFICATION
4 44. M/S. CLIANTHA RESEARCH LIMITED, 45. M/S. CLIANTHA RESEARCH LIMITED, 46. M/S. CLIANTHA RESEARCH LIMITED, 47. M/S. CLIANTHA RESEARCH LIMITED, 48. M/S. CLIANTHA RESEARCH LIMITED, 49. M/S. CLIANTHA RESEARCH LIMITED, 50. M/S. CLIANTHA RESEARCH LIMITED, 51. M/S. CLIANTHA RESEARCH LIMITED, 52. M/S. CLIANTHA RESEARCH LIMITED, 53. M/S. CLIANTHA RESEARCH LIMITED, 54. M/S. DR. REDDY'S LABORATORIES LTD., HYDERABAD M/S. DR. REDDY'S LABORATORIES LTD., HYDERABAD M/S. DR. REDDY'S LABORATORIES LTD., HYDERABAD M/S. EUGIA PHARMA SPECIALITIES LTD., HYDERABAD M/S. GLENMARK GENERICS LTD., MUMBAI M/S. GLENMARK GENERICS LTD., MUMBAI M/S. GLENMARK PHARMACEUTICALS LTD., NAVI CLARIFICATION CLARIFICATION CLARIFICATION CLARIFICATION CLARIFICATION CLARIFICATION CLARIFICATION CLARIFICATION TEST LICENCE TEST LICENCE CLARIFICATION CLARIFICATION CLARIFICATION CLARIFICATION CLARIFICATION CLARIFICATION APPROVAL
5 MUMBAI M/S. HETERO LABS LTD., 62. M/S. HETERO LABS LTD., 63. M/S. HETERO LABS LTD., 64. M/S. HETERO LABS LTD., 65. M/S. HETERO LABS LTD., 66. M/S. HETERO LABS LTD., 67. M/S. HETERO LABS LTD., 68. M/S. HETERO LABS LTD., 69. M/S. HETERO LABS LTD., 70. M/S. JAI PHARMA LTD., MUMBAI M/S. JAI PHARMA LTD., MUMBAI M/S. LAMBDA THERAPEUTIC 73. M/S. LAMBDA THERAPEUTIC 74. M/S. LAMBDA THERAPEUTIC 75. M/S. LAMBDA THERAPEUTIC CLARIFICATION CLARIFICATION CLARIFICATION CLARIFICATION CLARIFICATION APPROVAL APPROVAL TEST LICENCE TEST LICENCE 9627 CLARIFICATION 9628 CLARIFICATION CLARIFICATION CLARIFICATION CLARIFICATION CLARIFICATION
6 76. M/S. LAMBDA THERAPEUTIC 77. M/S. LAMBDA THERAPEUTIC 78. M/S. LAMBDA THERAPEUTIC 79. M/S. LAMBDA THERAPEUTIC 80. M/S. LAMBDA THERAPEUTIC 81. M/S. LAMBDA THERAPEUTIC 82. M/S. LAMBDA THERAPEUTIC 83. M/S. LAMBDA THERAPEUTIC 84. M/S. LAMBDA THERAPEUTIC 85. M/S. LAMBDA THERAPEUTIC 86. M/S. LAMBDA THERAPEUTIC 87. M/S. LAMBDA THERAPEUTIC RESEARCH LTD., NAVI MUMBAI M/S. LAMBDA THERAPEUTIC RESEARCH LTD., NAVI MUMBAI CLARIFICATION CLARIFICATION CLARIFICATION CLARIFICATION CLARIFICATION CLARIFICATION CLARIFICATION 7220 APPROVAL APPROVAL TEST LICENCE TEST LICENCE APPROVAL TEST LICENCE
7 M/S. LAMBDA THERAPEUTIC RESEARCH LTD., NAVI MUMBAI M/S. LOTUS LABS PVT. LTD., BANGALORE M/S. LUPIN LIMITED (RESEARCH PARK), PUNE M/S. LUPIN LIMITED (RESEARCH PARK), PUNE M/S. LUPIN LIMITED (RESEARCH PARK), PUNE M/S. LUPIN LIMITED (RESEARCH PARK), PUNE M/S. LUPIN LIMITED (RESEARCH PARK), PUNE M/S. MANIPAL ACUNOVA LTD., MANIPAL M/S. MSN LABORATORIES PVT. LTD., 98. M/S. MYLAN LABORATORIES LTD., BANGALORE M/S. NORWICH CLINICAL SERVICES PVT. LTD., BANGALORE M/S. NORWICH CLINICAL SERVICES PVT. LTD., BANGALORE M/S. PAR BIOSCIENCES PVT. LTD., PALLIKARANAI M/S. RA CHEM PHARMA LTD., HYDERABAD M/S. RAPTIM RESEARCH LTD., NAVI MUMBAI M/S. SEMLER RESEARCH CENTER PVT. LTD., BANGALORE TEST LICENCE AMENDMENT CLARIFICATION 7854 APPROVAL 7855 APPROVAL APPROVAL APPROVAL CLARIFICATION CLARIFICATION CLARIFICATION CLARIFICATION TEST LICENCE CLARIFICATION CLARIFICATION 7362 APPROVAL CLARIFICATION
8 105. M/S. SUN PHARMA ADVANCED RESEARCH COMPANY LTD., VADODARA M/S. SUN PHARMA ADVANCED RESEARCH COMPANY LTD., VADODARA M/S. SUN PHARMACEUTICAL INDUSTRIES LTD., GURGAON M/S. SUN PHARMACEUTICAL INDUSTRIES LTD., GURGAON M/S. SUN PHARMACEUTICAL INDUSTRIES LTD., HARYANA 110. M/S. SUN PHARMACEUTICAL INDUSTRIES LTD., HARYANA 111. M/S. SUN PHARMACEUTICAL INDUSTRIES LTD., VADODARA M/S. SUN PHARMACEUTICAL INDUSTRIES LTD., VADODARA M/S. SUN PHARMACEUTICAL INDUSTRIES LTD., VADODARA M/S. SUN PHARMACEUTICAL INDUSTRIES LTD., VADODARA M/S. SUN PHARMACEUTICAL INDUSTRIES LTD., VADODARA M/S. SUN PHARMACEUTICAL INDUSTRIES LTD., VADODARA M/S. SUN PHARMACEUTICAL INDUSTRIES LTD., VADODARA APPROVAL APPROVAL CLARIFICATION CLARIFICATION APPROVAL AMENDMENT 3305 APPROVAL CLARIFICATION CLARIFICATION APPROVAL APPROVAL APPROVAL AMENDMENT
9 118. M/S. SYNGENE INTERNATIONAL LTD., BANGALORE M/S. VEEDA CLINICAL RESEARCH PVT. LTD., AHMEDABAD M/S. VEEDA CLINICAL RESEARCH PVT. LTD., AHMEDABAD M/S. VEEDA CLINICAL RESEARCH PVT. LTD., AHMEDABAD M/S. VEEDA CLINICAL RESEARCH PVT. LTD., AHMEDABAD M/S. VEEDA CLINICAL RESEARCH PVT. LTD., AHMEDABAD M/S. VEEDA CLINICAL RESEARCH PVT. LTD., AHMEDABAD M/S. VIMTA LABS LTD., HYDERABAD M/S. WATSON PHARMA PVT. LTD., NAVI MUMBAI M/S. WATSON PHARMA PVT. LTD., NAVI MUMBAI M/S. WATSON PHARMA PVT. LTD., NAVI MUMBAI M/S. WOCKHARDT LIMITED, AURANGABAD M/S. WOCKHARDT LIMITED, AURANGABAD CLARIFICATION CLARIFICATION CLARIFICATION CLARIFICATION CLARIFICATION APPROVAL APPROVAL APPROVAL CLARIFICATION AMENDMENT AMENDMENT APPROVAL TEST LICENCE BIOLOGICAL DIVISION S. NO. COMPANY NAME/ FILE NO 1 M/S NOVO NORDISK INDIA PVT, LTD DY. NO STATUS INVITATION
10 2 M/S GSK LTD INVITATION 3 M/S BIOGENOMICS LTD INVITATION 4 M/S NOVARTIS HEALTHCARE LTD 5 M/S RELIANCE LIFE SCIENCES PVT, LTD INVITATION INVITATION 6 M/S SANDOR MEDICAIDS INVITATION 7 M/S CADILA HEALTHCARE LTD 8 M/S BHARAT BIOTECH INTERNATIONAL LTD INVITATION INVITATION BA/BE DIVISION S. NO. COMPANY NAME FTS NO. /DIARY NO. STATUS 01 M/S. MYLAN LABORATORIES, HYDERABAD 7060 QUERY 02 M/S. ACTIMUS BIOSCIENCES, VISHAKHAPATNAM QUERY COSMETIC DIVISION S.NO. COMPANY NAME DIARY NO. STATUS 1. M/S. PRIIS TRADING COMPANY, ERNAKULAM FTS NO APPROVAL SUBSEQUENT NEW DRUG S. NO. NAME OF THE FIRM REFERENCE NO. FTS NO. TYPE OF
11 1. M/S SUN PHARMA - - SEC INVITATION (GASTROLOGY & HEPATOLOGY) & (DERMATOLOGY) M/S NOVARTIS - - SEC INVITATION (GASTROLOGY & HEPATOLOGY) M/S LINCOLN - - SEC INVITATION (ANALGESIC) M/S NU THERAPEUTICS - - SEC INVITATION (REPRODUCTIVE & UROLOGY) M/S CADILA HEALTHCARE - - SEC INVITATION (ANALGESIC) M/S TROIKAA - - SEC INVITATION (ANALGESIC) M/S MICRO LABS APPROVAL 8. M/S CAIDLA DEFICIENCY PHARMACEUTICALS 9. M/S IPCA LABORATORIES DEFICIENCY 10. M/S PRECISE CHEMIPHARMA IPC TESTING REGISTRATION S.NO. NAME OF APPLICANT DIARY NO. TYPE OF 1. ANZEN EXPORTS 4928 APPROVAL 2. SHAH TC 38178, APPROVAL 3. DIVINNE SBR 51251, APPROVAL 4. KENKO CORPORATION 6147 APPROVAL 5. JSN PHARMATECH 5606 APPROVAL 6. K.P.MANISH GLOBAL INGREDIENTS PVT. LTD. 644 APPROVAL 7. ARCHERCHEM 3960 APPROVAL 8. UTKARSH OVERSEASE PVT.LTD APPROVAL 9. FERTIN INDIA PVT LTD APPROVAL 10. EASTERN CHEMICALS PVT. LTD APPROVAL 11. TRICHEM 5004 APPROVAL
12 12. LUNDBECK INDIA PVT. LTD. 529 APPROVAL 13. COLGATE PALMOLIVE INDIA LTD APPROVAL 14. MSD PHARAMCEUTICALS PVT. LTD APPROVAL 15. BESINS HEALTHCARE INDIA PVT. LTD APPROVAL 16. ANZEN EXPORTS 4532 CALRIFICATION 17. WOCKHARDT LTD ,13295 CALRIFICATION 18. VITUS GLOBAL INC CALRIFICATION 19. U.S.V. PVT. LTD CALRIFICATION 20. OMEX INTERNATIONAL CALRIFICATION 21. UNI-CHEMIE INTERNATIONAL 29699,19092, 06 CALRIFICATION 37199,29657, KAWARLAL CDEF CALRIFICATION 23. EMCURE PHARMACETUICAL LTD CALRIFICATION 24. ALLIANCE PHARMA AGENCIES CALRIFICATION 25. NUB CHEM CALRIFICATION 26. RIFA PHARMA CALRIFICATION CALRIFICATION 27. GLAXO SMITHKLINE PHARMACETUICALS LTD CALRIFICATION 28. G.K. EXIM 2110 CALRIFICATION 29. RUSKIN CHEMIPHARM NIL CALRIFICATION 30. SYMBIO GENERICS INDIA PVT. LTD. NIL VITAL HEALTHCARE PVT. LTD. NIL CALRIFICATION 32. SHAH TC CALRIFICATION 33. NEWCHEM SPA CALRIFICATION 34. COSMOS INTERNATIONAL CALRIFICATION 35. SAI QUEST SYN PVT. LTD. NIL CALRIFICATION 36. DPB ANTIBIOTICS PVT. LTD. NIL CALRIFICATION 37. BLUESTREAM MANUFACTURING SERIVICES 3905 CALRIFICATION PVT. LTD. 38. BAYER PHARMACEUTICALS PVT. LTD. 4925, CALRIFICATION 39. SENARU FORMULATION PVT. LTD CALRIFICATION 40. EMCURE PHARMACEUTICALS LTD CALRIFICATION 41. NOVARTIS INDIA LTD CALRIFICATION 42. ROCHE PRODUCTS INDIA PVT. LTD CALRIFICATION 43. MERCK SPECIALITIES PVT. LTD CALRIFICATION 44. B.BRAUN MEDICAL INDIA PVT. LTD CALRIFICATION 45. CLAIRVOYANCE CONSULTING CALRIFICATION 46. COLGATE PALMOLIVE INDIA LTD CALRIFICATION 47. SCIENTIFIC REMEDIES PVT. LTD CALRIFICATION 48. EISAI PHARMACEUTICALS INDIA PVT. LTD CALRIFICATION 49. SANOFI INDIA LTD. 2941,1505 AMENDED
13 50. ANANTCO ENTERPRISES PVT. LTD AMENDED 51. ALLIED PHARMA SOLUTIONS 9782 AMENDED 52. SHAH TC 22226, AMENDED 53. ESSCHEM PVT. LTD. 8579,8578, AMENDED 54. UNI-CHEMIE INTERNAIONAL 5216, AMENDED 55. SINOPHARM INDIA PVT. LTD AMENDED 56. ETHACHEM 4943 AMENDED 57. SEKISUI CHEMICAL INDIA PVT. LTD. NIL AMENDED 58. GLAXOSMITHKLINE PHARMACEUTICALS LTD AMENDED 59. GALANTA PHARMA PVT. LTD. 985 AMENDED 60. MERK SPECIALTIES PVT. LTD AMENDED 61. LUPIN LTD AMENDED 62. MSD PHARMACEUTICAL PVT. LTD AMENDED 63. ROCHE PROUDCTS INDIA PVT. LTD AMENDED 64. PFIZER LTD AMENDED 65. JOHNSON &JOHNSON PVT. LTD 86 AMENDED 66. PFIZER PROUDCTS INDIA PVT. LTD AMENDED 67. BAYER PHARMACEUTICALS PVT. LTD AMENDED MEDICAL DEVICE S.NO. COMPANY NAME DIARY NO STATUS 1. M/S. ABBOTT MEDICAL OPTICS PVT. LTD APPROVAL (R-RC) 2. M/S. ABBOTT MEDICAL OPTICS PVT. LTD APPROVAL (R-RC) 3. M/S. BIOTRONIK MEDICAL DEVICES INDIA PVT. LTD APPROVAL (F-RC) 4. M/S. BOSTON SCIENTIFIC INDIA PVT. LTD APPROVAL (E-RC) 5. M/S. COVIDIEN HEALTHCARE INDIA PVT. LTD APPROVAL (F-RC) 6. M/S. EISAI PHARMACEUTICALS INDIA PVT. LTD APPROVAL (F-RC) 7. M/S. EMERGO (INDIA) CONSULTING PVT. LTD APPROVAL (F-RC) 8. M/S. EMERGO (INDIA) CONSULTING PVT. LTD APPROVAL (F-RC) 9. M/S. JOHNSON & JOHNSON PVT. LTD APPROVAL (F-RC) 10. M/S. MERIL LIFE SCIENCES INDIA PVT. LTD APPROVAL (R-E-RC) 11. M/S. MONARCH ENTERPRISES 8871 APPROVAL (F-RC)
14 12. M/S. MED-EL INDIA PVT. LTD APPROVAL (R-RC) 13. M/S. PHOENIX MEDICARE PVT. LTD APPROVAL (F-RC) 14. M/S. SHAH DISTRIBUTORS 6542 APPROVAL (R-RC) 15. M/S. SMITH & NEPHEW HEALTHCARE PVT. LTD APPROVAL (R-E-RC) 16. M/S. SMITH & NEPHEW HEALTHCARE PVT. LTD APPROVAL (F-RC) 17. M/S. SMITH & NEPHEW HEALTHCARE PVT. LTD APPROVAL (R-E-RC) 18. M/S. SANOFI SYNTHELABO (INDIA) PVT. LTD APPROVAL (F-RC) 19. M/S. TERUMO INDIA PVT. LTD APPROVAL (F-RC) 20. M/S. ARTHROCARE MEDICAL DEVICE INDIA PVT. LTD APPROVAL (E-RC) 21. M/S. ABBOTT MEDICAL OPTICS PVT. LTD APPROVAL (R-IL) 22. M/S. ABBOTT MEDICAL OPTICS PVT. LTD APPROVAL (R-IL) 23. M/S. BOSTON SCIENTIFIC INDIA PVT. LTD APPROVAL (E-IL) 24. M/S. B. BRAUN MEDICAL INDIA PVT. LTD APPROVAL (F-IL) 25. M/S. COVIDIEN HEALTHCARE INDIA PVT. LTD APPROVAL (F-IL) 26. M/S. EISAI PHARMACEUTICALS INDIA PVT. LTD APPROVAL (F-IL) 27. M/S. JOHNSON & JOHNSON PVT. LTD APPROVAL (F-IL) 28. M/S. MERIL LIFE SCIENCES INDIA PVT. LTD APPROVAL (R-E-IL) 29. M/S. MONARCH ENTERPRISES 8871 APPROVAL (F-IL) 30. M/S. PHOENIX MEDICARE PVT. LTD APPROVAL (F-IL) 31. M/S. SHAH DISTRIBUTORS 6542 APPROVAL (R-IL) 32. M/S. SMITH & NEPHEW HEALTHCARE PVT. LTD APPROVAL (R-E-IL) 33. M/S. SMITH & NEPHEW HEALTHCARE PVT. LTD APPROVAL (F-IL) 34. M/S. SMITH & NEPHEW HEALTHCARE PVT. LTD APPROVAL (R-E-IL) 35. M/S. SMITH & NEPHEW HEALTHCARE PVT. LTD M/S. TERUMO INDIA PVT. LTD APPROVAL (F-IL) 37. M/S. VERITAS BIOVENTIONS PVT. LTD APPROVAL (R-IL)
15 38. M/S. ROMSONS SCIENTIFIC AND SURGICAL INDUSTRIES PVT. LTD AMENDMENT 39. M/S. EMERGO (INDIA) CONSULTING PVT. LTD M/S. EXCEL MARKETING CORPORATION 9357 APPROVAL (F-RC) 41. M/S. EXCEL MARKETING CORPORATION 9357 QUERY 42. M/S. MITRA INDUSTRIES PVT. LTD. FTS. NO M/S. MITRA INDUSTRIES PVT. LTD. FTS. NO CLARIFICATION CLARIFICATION 44. M/S. JOHNSON & JOHNSON PVT. LTD AMENDMENT 45. M/S. JOHNSON & JOHNSON PVT. LTD QUERY 46. M/S. STRYKER INDIA PVT. LTD AMENDMENT 47. M/S. SMITH & NEPHEW HEALTHCARE PVT. LTD M/S. EMERGO (INDIA) CONSULTING PVT. LTD CLARIFICATION 49. M/S. PRO MEDIC DEVICES CLARIFICATION 50. M/S. ENCARTA PHARMA PVT. LTD M/S. MERIL LIFE SCIENCES INDIA PVT. LTD. FTS. NO M/S. ZIMMER INDIA PVT. LTD QUERY 53. M/S. ZIMMER INDIA PVT. LTD QUERY 54. THE COMMISSIONER, GANDHINAGAR (CLAA) THE DEPUTY DRUGS CONTROLLER, AHMEDABAD (CLAA) M/S. SOLCO BIOMEDICAL CO. (INDIA) PVT. LTD. 55. THE COMMISSIONER, GANDHINAGAR (CLAA) THE DEPUTY DRUGS CONTROLLER, AHMEDABAD (CLAA) M/S. OMEX MEDICAL TECHNOLOGY, MEHSANA 56. THE DRUGS LICENSING & CONTROLLING AUTHORITY, LUCKNOW (CLAA) FTS. NO. - NIL FTS. NO. - NIL FTS. NO. - NIL QUERY
16 THE DEPUTY DRUGS CONTROLLER, GHAZIABAD(CLAA) M/S. NARANG MEDICAL LTD., GHAZIABAD 57. THE STATE DRUGS CONTROLLER, PANCHKULA (CLAA) THE DEPUTY DRUGS CONTROLLER, GHAZIABAD(CLAA) (M/S. POLY MEDICURE LTD., FARIDABAD) 58. M/S. MERIL LIFE SCIENCES PVT. LTD., VALSAD (CLAA) THE COMMISSIONER, GANDHINAGAR (CLAA) 59. THE COMMISSIONER, GANDHINAGAR (CLAA) THE DEPUTY DRUGS CONTROLLER, AHMEDABAD (CLAA) (M/S. MERIL LIFE SCIENCES PVT. LTD., VALSAD) 60. ALL PORT OFFICES OF CDSCO M/S. RF HEALTHCARE, CHENNAI M/S. WIN SURGICAL, MUMBAI FTS. NO FTS. NO FTS. NO NIL APPROVAL APPROVAL 61. M/S. STRYKER INDIA PVT. LTD APPROVAL (R-RC) 62. M/S. STRYKER INDIA PVT. LTD APPROVAL (R-IL) DIAGNOSTICS DIVISION S.NO. COMPANY NAME DIARY NO STATUS 1. M/S. ASPEN DIAGNOSTICS PVT. LTD APPROVAL (IL) (ONLINE APPROVAL ) 2. M/S. JOHNSON & JOHNSON PVT. LTD APPROVAL (IL) (ONLINE APPROVAL ) 3. M/S. ONSITE DIAGNOSTICS LABS INDIA PVT. LTD APPROVAL (IL) (ONLINE APPROVAL )
17 4. M/S. VISHAT DIAGNOSTICS PVT. LTD. 975 APPROVAL (IL) (ONLINE APPROVAL ) 5. M/S. ABBOTT HEALTHCARE PVT. LTD APPROVAL (IL) 6. M/S. ACCUREX BIOMEDICAL PVT. LTD APPROVAL (IL) 7. M/S. ASPEN LABORATORIES APPROVAL (IL) 8. M/S. ASPEN DIAGNOSTICS PVT. LTD APPROVAL (IL) 9. M/S. BECKMAN COULTER INDIA PVT. LTD APPROVAL (IL) 10. M/S. BECKMAN COULTER INDIA PVT. LTD APPROVAL (IL) 11. M/S. ORTHO CLINICAL DIAGNOSTIC INDIA PVT. LTD APPROVAL (IL) 12. M/S. OPERON BIOTECH AND HEALTHCARE 7483 APPROVAL (IL) 13. M/S. RAPID DIAGNOSTICS PVT. LTD APPROVAL (IL) 14. M/S. SD BIOSENSOR HEALTHCARE PVT. LTD APPROVAL (E-IL) 15. M/S. SIRUS BIOCARE PVT. LTD APPROVAL (RENEWAL- IL) 16. M/S. TOSOH INDIA PVT. LTD APPROVAL (IL) 17. M/S. TOSOH INDIA PVT. LTD QUERY 18. M/S. MICROGENE DIAGNOSTICS SYSTEMS PVT. LTD APPROVAL(TEST LICENSE) 19. M/S. AIMS 4462 QUERY 20. M/S. BECTON DICKINSON INDIA PVT. LTD QUERY 21. M/S. BIO-RAD LABORATORIES (INDIA) PVT. LTD QUERY 22. M/S. BIO-RAD LABORATORIES (INDIA) PVT. LTD QUERY 23. M/S. BIO-RAD LABORATORIES (INDIA) PVT. LTD QUERY 24. M/S. BIO-RAD LABORATORIES (INDIA) PVT. LTD QUERY 25. M/S. PAMMVI EXPORTS PVT. LTD QUERY 26. M/S. ROCHE DIAGNOSTICS INDIA PVT. LTD. 9208
LETTERS FOR ISSUE ON
S FOR ISSUE ON 15.10.2015 INTERNATIONAL CELL S. NO FIRM NAME TYPE 1 M/S NATCO PHARMA LIMITED HYDERABAD MEDICAL DEVICE S.NO. COMPANY NAME DIARY NO STATUS 1. M/S. GENETIX BIOTECH ASIA PVT. LTD. 22073 APPROVAL
LETTERS FOR ISSUE ON
S FOR ISSUE ON 14.03.2016 IMPORT S.NO. NAME OF APPLICANT DIARY NO. TYPE OF 1. TABLETS (INDIA) LIMITED 5973 APPROVAL 2. TABLETS (INDIA) LIMITED 5974 APPROVAL 3. CLARIS OTSUKA PRIVATE LIMITED 7373 APPROVAL
LETTERS FOR ISSUE ON
S FOR ISSUE ON 21.06.2016 LVP DIVISION S. NO. COMPANY NAME FTS NO. /DIARY NO. STATUS 01 M/S. GLOBAL PHARMA HEALTHCARE PVT. LTD., THIRUPORUR 27509 APPROVAL BIOLOGICAL DIVISION NAME OF COMPANY DY.NO. STATUS
LETTERS FOR ISSUE ON
S FOR ISSUE ON 17.07.2015 NEW DRUG S.NO. NAME OF APPLICANT DIARY TYPE OF NO. 1. M/S. CIREX PHARMACEUTICALS LTD - QUERY 2. M/S. LUPIN LIMITED - ADDITIONAL SITES REGISTRATION S.NO. NAME OF APPLICANT DIARY
LETTERS FOR ISSUE ON
S FOR ISSUE ON 19.06.2015 BE NOC FOR EXPORT S. NO. NAME OF THE COMPANY REF. NO. TYPE OF 1. M/S. ACCUTEST RESEARCH LABORATORIES (I) PVT., NAVI MUMBAI-400 709 2. M/S. ACCUTEST RESEARCH LABORATORIES (I) PVT.,
LETTERS FOR ISSUE ON
S FOR ISSUE ON 04.12.2015 NEW DRUG S.NO. NAME OF APPLICANT DIARY NO. TYPE OF 1. M/S. VIRCHOW BIOTECH PVT LTD - QUERY 2. M/S. MSN LABORATORIES PVT - CT-NOC & BE NOC LTD (3) 3. M/S. NATCO PHARMA LTD. - BE-NOC
LETTERS FOR ISSUE ON
S FOR ISSUE ON 14.12.2015 LVP DIVISION S. COMPANY NAME FTS /DIARY STATUS 01 M/S. AXA PARENTERALS LTD., ROORKEE 60262 APPROVAL 02 M/S. UNIJULES LIFE SCIENCES LTD., NAGPUR 61147 APPROVAL 03 M/S. INNVOL MEDICAL
LETTERS FOR ISSUE ON
S FOR ISSUE ON 05.10.2015 INTERNATIONAL CELL S. NO FIRM NAME TYPE OF DOCUMENT 1. M/S. ARRIGO INTERNATIONAL,INDORE 2 M/S. EUROLIFE HEALTHCARE PVT. LTD. HARIDWAR NEW DRUG S. NAME OF APPLICANT DIARY TYPE
LETTERS FOR ISSUE ON
S FOR ISSUE ON 03.09.2015 INTERNATIONAL CELL S. NO FIRM NAME TYPE 1. M/S LUPIN TARAPUR, MAHARASHTRA & WC 2. M/S JPN PHARMA PVT. PALGHAR, MAHARASHTRA WC 3. M/S OPTIMUS DRUGS A.P. WC VACCINE DIVISION S.
LETTERS FOR ISSUE ON
S FOR ISSUE ON 29.11.2016 COSMETICS DIVISION S.NO. NAME OF APPLICANT DIARY NO. TYPE OF 1. M/S. WELLA INDIA PVT. LTD., MUMBAI 29233, 29524 & 28513 APPROVAL 2. M/S. PROCTER & GAMBLE HOME PRODUCTS PVT. LTD.,
LETTERS FOR ISSUE ON
S FOR ISSUE ON 04.10.2017 MEDICAL DEVICE DIVISION S.NO. COMPANY NAME DIARY NO STATUS 1. M/S. ABBOTT MEDICAL OPTICS PVT. LTD., 14608 QUERY 2. M/S. ABBOTT MEDICAL OPTICS PVT. LTD., 14609 QUERY 3. DR. ULHAS
LETTERS FOR ISSUE ON
S FOR ISSUE ON 11.04.2017 BIOLOGICAL DIVISION NAME OF COMPANY DY. NO. STATUS M/S ZUVENTUS HEALTHCARE LTD 6981 APPROVAL M/S TECHINVENTION LIFE SCIENCES 1208 CLARIFICATION M/S CADILA PHARMACEUTICALS LTD
LETTERS FOR ISSUE ON
S FOR ISSUE ON 25.04.2017 BE NOC FOR EXPORT S. NO. NAME OF THE COMPANY REF. NO. TYPE OF 1. M/S. ALEMBIC PHARMACEUTICALS 2. M/S. ALEMBIC PHARMACEUTICALS 3. M/S. ALEMBIC PHARMACEUTICALS 4. M/S. EMCURE PHARMACEUTICALS
LETTERS FOR ISSUE ON
S FOR ISSUE ON 01.09.2015 INTERNATIONAL CELL S. NO FIRM NAME TYPE 1. M/S TYCHE INDUSTRIES LTD., ANDHRA PRADESH, INDIA IMPORT S. NAME OF APPLICANT DIARY TYPE OF 1. PIRAMAL ENTERPRISES LTD. 25471 APPROVAL
LETTERS FOR ISSUE ON
S FOR ISSUE ON 27.08.2015 NEW DRUG S. NAME OF APPLICANT DIARY TYPE OF 1. M/S. INTAS PHARMACEUTICALS LIMITED - CT NOC (2) 2. M/S. PFIZER LIMITED - QUERY 3. M/S. MSN LABORATORIES - ADDITIONAL SITE 4. M/S.
TODAY LETTER DATED
TODAY LETTER DATED 26.06.2018 GLOBAL CLINICAL TRIAL SR. NO. COMPANY NAME REFERENCE NO. STATUS 1 M/S. RESEARCH ASSOCIATES INDIA PVT.. 18670 PA APPROVAL LETTER LVP DIVISION S. NO. COMPANY NAME FTS NO. /DIARY
LETTERS FOR ISSUE ON
LETTERS FOR ISSUE ON 27.12.2017 LVP DIVISION S. NO. COMPANY NAME FTS NO. /Diary No. STATUS 01 M/s. Akums Drugs & Pharmaceuticals, Haridwar 02 M/s. Unique Pharmaceutical Laboratories,Guj. (License No.4)
RESULTS AND DISCUSSION
RESULTS AND DISCUSSION 203 4.1 General Introduction: The researcher has collected both the primary and secondary data. The primary data is collected by direct interaction by using formal questionnaire
REGULATORY UPDATES: APPROVAL, DENIALS AND AGREEMENTS REGULATORY UPDATES: APPROVAL, (CONTINUED)... 38
CHAPTER ONE: INTRODUCTION... 1 STUDY OBJECTIVES... 1 REASONS FOR DOING THIS STUDY... 1 INTENDED AUDIENCE... 2 SCOPE OF THE STUDY... 2 METHODOLOGY... 2 INFORMATION SOURCES... 2 ABOUT THE AUTHOR... 3 RELATED
Recommendations of thesec (Dermatology & Allergy) made in its 23 rd meeting held on at CDSCO HQ New Delhi: New Drugs Division
Recommetions of thesec (Dermatology & Allergy) made in its 23 rd meeting held on 11.05.2017 at CDSCO HQ New Delhi: File /Drug Name Recommetions New Drugs Division 1 12-28/15-DC (Pt-B) Apremilast 10/20/30
BRIC DIABETES DRUGS MARKET
BRIC DIABETES DRUGS MARKET R e p o r t D e s c r i p t i o n T a b l e o f C o n t e n t s L i s t o f T a b l e s S a m p l e T a b l e s R e l a t e d R e p o r t s A b o u t M a r k e t s a n d M a
File no./drug Name Name of firm/ Institute Recommendations. New Drugs Division
Recommendations: I approve the minutes of 52 nd SEC (Oncology & hematology) held on 13.04.2017 at CDSCO HQ New Delhi and recommended the following: Agenda 1 12-63/16-DC Ferric Pyrophosphate citrate solution
THE CORPORATE REPUTATION OF PHARMA 2015 THE PERSPECTIVE OF 139 PATIENT GROUPS with an interest in DIABETES
THE CORPORATE REPUTATION OF PHARMA 2015 THE PERSPECTIVE OF 139 PATIENT GROUPS with an interest in DIABETES PUBLISHED AUGUST 2016 There is growing distrust of pharma in light of several recent and dramatic
3. Dr.Rajutitus Chacko, Prof. & Head, Dept. of Medical Oncology, CMC, Vellore.
MINUTES OF THE 6 th MEETING OF TECHNICAL COMMITTEE HELD ON 25-07-2013 UNDER CHAIRMANSHIP OF DGHS FOR SUPERVISING CLINICAL TRIALS ON NEW CHEMICAL ENTITIES IN THE LIGHT OF DIRECTIONS OF THE HON BLE SUPREME
Status of Import License (Form 10) of Recombinant Products, Human and Veterinary Vaccines issued from 01/03/2016 to 29/04/2016
1. M/s LG Life Sciences India Pvt. Ltd.,Basement Commercial SCO No. 321, Sector-29, Gurgaon, India 2. M/s Eli Lilly and Co (I) Pvt. Ltd., Bldg. No. 14, Gala No. 1 to 4, 1 st Fl, Arihant Comm. Complex,
WHO PUBLIC INSPECTION REPORT (WHOPIR) Contract Research Organization
SOP 408.4 Annex C 20, avenue Appia CH-1211 Geneva 27 Switzerland Tel central +41 22 791 2111 Fax central +41 22 791 3111 www.who.int Part 1: General information WHO PUBLIC INSPECTION REPORT (WHOPIR) Contract
PHARMACEUTICALS EXPORT PROMOTION COUNCIL OF INDIA
1 Agio Pharmaceuticals Limited 15/31/2013-EP(Engg) dt:21.11.2013 7,98,217.00 2 Akriti Pharmaceuticals Pvt Ltd 15/31/2013-EP(Engg) dt:21.11.2013 15,10,268.00 3 Akriti Pharmaceuticals Pvt Ltd 15/31/2013-EP(Engg)
10 th SEC- (Reproductive & Urology)meetingheld on at CDSCO (HQ), FDA Bhawan, Kotla road, New Delhi PROGRAMME SCHEDULE
10 th SEC- (Reproductive & Urology)meetingheld on 16-01-2015 at CDSCO (HQ), FDA Bhawan, Kotla road, New Delhi 110 002 PROGRAMME SCHEDULE Recommendation:- The 10 th SEC (Reproductive and Urology) meeting
GLOBAL MARKETS FOR DIABETES THERAPEUTICS AND DIAGNOSTICS
GLOBAL MARKETS FOR DIABETES THERAPEUTICS AND DIAGNOSTICS HLC029D January 2013 Paul Evers Project Analyst ISBN: 0-89336-238-7 BCC Research 49 Walnut Park, Building 2 Wellesley, MA 02481 866-285-7215, 781-489-7301
Status of Registration Certificate (Form 41) of Human Vaccines issued from 01/03/2015 to 29/05/2015. Human vaccines
Status of Registration Certificate (Form 41) of Human Vaccines issued from 01/03/2015 to 29/05/2015 S. No. Firm Name of Formulation Registration Certificate No. & Validity 1. M/s. Nirlac Chemicals,14 th
US pharmaceutical market: trends, issues, forecast. Doug Long Vice President Industry Relations IMS Health
US pharmaceutical market: trends, issues, forecast Doug Long Vice President Industry Relations IMS Health 2006 Strategic management review The World Pharmaceutical Market All reproduction rights, quotations,
GLOBAL MARKETS FOR TREATMENT AND DIAGNOSIS OF SEXUALLY TRANSMITTED DISEASES
GLOBAL MARKETS FOR TREATMENT AND DIAGNOSIS OF SEXUALLY TRANSMITTED DISEASES PHM005C January 2013 Peggy Lehr Project Analyst ISBN: 0-89336-646-3 BCC Research 49 Walnut Park, Building 2 Wellesley, MA 02481
Education. Current Activities
Nirali Mehta, M.Sc., M.Phil. Founder & Consultant Biostatistician Ahmedabad, Gujarat, India. M +91 9377060504 E nirali.mehta@pharma-stats.in W www.pharma-stats.in Education 1998-2001 Bachelor of Science
CHAPTER FOUR: UPDATE ON THE AIDS PANDEMIC TABLE 2 MILESTONES IN THE HISTORY OF HIV/AIDS TABLE 2 (CONTINUED) REGIONAL OVERVIEW...
CHAPTER ONE: INTRODUCTION... 1 STUDY GOALS AND OBJECTIVES... 1 REASONS FOR DOING THE STUDY... 1 SCOPE OF REPORT... 1 MARKET ANALYSES AND FORECASTS... 2 INTENDED AUDIENCE... 2 INFORMATION SOURCES... 2 ANALYST
Recent trends and challenges
INTERNATIONAL CONFERENCE ON Recent trends and challenges in Bioanalysis Tentative Program Bioanalytica-2017 Hyderabad,India JUNE 30, 2017 Invitation ABC Biologics welcomes you to attend the international
Minimumum Price (Rs.) 3.30 Maximum Price (Rs.) 4.57 Average of all considered (Rs.) 3.73 Retail Price (Rs.) 4.33
Computataion of Retail Price based on Jan.-2016 Data under Para 4 of DPCO 2013 Cholecalciferol 800 IU Drops of M/s Raptakos, Brett & Co.Ltd. Number of Companies cosisting of Market Share of 1% & Above
PDF of Trial CTRI Website URL -
Clinical Trial Details (PDF Generation Date :- Sun, 02 Sep 2018 23:38:24 GMT) CTRI Number Last Modified On 05/02/2015 Post Graduate Thesis Type of Trial Type of Study Study Design Public Title of Study
Organ Transplantation Market Research Report- Global Forecast Till 2023
Report Information More information from: https://www.marketresearchfuture.com/reports/915 Organ Transplantation Market Research Report- Global Forecast Till 2023 Report / Search Code: MRFR/HC/0410-HCRR
Case 1:14-cv LPS Document 195 Filed 01/05/16 Page 1 of 5 PageID #: 6023
Case 1:14-cv-00121-LPS Document 195 Filed 01/05/16 Page 1 of 5 PageID #: 6023 IN THE UNITED STATES DISTRICT COURT FOR THE DISTRICT OF DELAWARE FOREST LABO RA TORIES, INC., FOREST LABO RA TORIES HOLDINGS,
Case 3:15-cv PGS-TJB Document 1 Filed 08/04/15 Page 1 of 111 PageID: 1 ) ) ) ) ) ) ) ) ) ) ) ) ) ) ) ) ) ) ) ) ) ) )
Case 3:15-cv-05982-PGS-TJB Document 1 Filed 08/04/15 Page 1 of 111 PageID: 1 Liza M. Walsh Christine I. Gannon CONNELL FOLEY LLP One Newark Center 1085 Raymond Boulevard, 19th Floor Newark, New Jersey
TRADE MARKS REGISTRY AHMEDABAD
TRADE MARKS REGISTRY AHMEDABAD OPPOSITION HEARING LIST FOR THE MONTH OF JUNE-2016 DATE OF HEARING 13.06.2016 1. 934855/05 Opp. AMD-245342 M/s. Ajanta Pharma Limited, Mumbai / Mr. Manoj G. Menda, Mumbai
Dataset : PharmaTrac MAT MAY PharmaTrac Overview MAY 18
PharmaTrac Overview MAY 18 8434 8956 9655 10422 8112 8917 9549 8258 8921 9406 8668 9630 9381 8662 8373 8999 9013 9796 10413 8742 9315 10050 8458 9180 8601 9092 9767 8364 9145 10583 10173 10387 10217 10476
Recommendation:- The 19 th SEC - (Oncology & Hematology) deliberated the proposals on and recommended the following:-
Recommendation:- The 19 th SEC - (Oncology & Hematology) deliberated the proposals on 05.11.2014 and recommended the following:- Agend a No. File No. 1. File No.: 12-75/13-DC Afatinib film coated tablet
Solvay in India January, 2014
Solvay in India January, 2014 SOLVAY in India, Innovation and Operational excellence Jodhpur Hichem (JV) Ahmedabad Hichem (JV) Bhiwani Hichem (JV) Delhi Hichem (JV) Solvay R&D center Vadodara Panoli Solvay
Ameya works predominantly in the architectural design, interiors and project management segments in healthcare industry
Introduction Ameya design is premier health care consultancy firm with experience with design and execution of largest number of private sector health care facility in India. Key Information Ameya works
A study on Metformin (1, 1-Dimethylbiguanidemonohydrochloride) reported adverse events as observed in Eudravigilance database
A study on Metformin (1, 1-Dimethylbiguanidemonohydrochloride) reported adverse events as observed in Eudravigilance database Contract Research Organization / Terzetto Pharma Metrics NIVETHA CHELLAPATHY
Tamsulosin Hydrochloride 0.4 mg Capsule
Tamsulosin Hydrochloride 0.4 mg Capsule, Tamsulosin Hydrochloride 0.4 mg Capsule India, Tamsulosin Hydrochloride 0.4 mg Capsule manufacturers India, side effects Tamsulosin Hydrochloride 0.4 mg Capsule
Hyderabad, India Delegates. April 27, Tentative program A comprehensive Bioanalysis conclave. Key notes.
INTERNATIONAL CONFERENCE &EXHIBITION Tentative program A comprehensive Bioanalysis conclave 7+ Key notes 50+ Poster presentations 100+ Delegates 2 + Panel Discussions April 27, 2018 Hyderabad, India Invitation
Case 2:09-cv DMC-CCC Document 1 Filed 03/20/2009 Page 1 of 95. Of Counsel:
Case 2:09-cv-01302-DMC-CCC Document 1 Filed 03/20/2009 Page 1 of 95 Charles M. Lizza William C. Baton SAUL EWING LLP One Riverfront Plaza Newark, NJ 07102 (973) 286-6700 clizza@saul.com Attorneys for Plaintiff
Oncology Pipeline Analytics
Oncology Pipeline Analytics Trials, Drug Classes, Indications, Correlations and Strategies Report Brochure O n c o l o g y P i p e l i n e A n a l y t i c s Greystone Research Associates is pleased to
Global Aspergillosis Drugs Market Professional Survey Report 2016
Report Information More information from: https://www.wiseguyreports.com/reports/526011 Global Aspergillosis Drugs Market Professional Survey Report 2016 Report / Search Code: WGR526011 Publish Date: 24
TRADE MARKS REGISTRY AHMEDABAD
TRADE MARKS REGISTRY AHMEDABAD OPPOSITION HEARING LIST FOR THE MONTH OF SPTEMBER-2013 DATE OF HEARING 10.09.2013 R. T. M. 1. 842945/16 Rect. AMD-249059 Mr. Pankajbhai Sitaram Nayak, Hearing on Section
Operatory Units TABLE 20 SELECT MANUFACTURERS AND DISTRIBUTORS OF DENTAL FURNITURE TABLE 20 (CONTINUED) Cavity Preparation Systems
CHAPTER ONE: INTRODUCTION... 1 STUDY GOALS AND OBJECTIVES... 1 REASONS FOR DOING THE STUDY... 1 SCOPE AND FORMAT... 1 METHODOLOGY... 1 RELATED BCC STUDIES... 2 ANALYST CREDENTIALS... 2 BCC ON-LINE SERVICES...
Global Vitamin Market Professional Survey Report 2016
Published on Market Research Reports Inc. (https://www.marketresearchreports.com) Home > Global Vitamin Market Professional Survey Report 2016 Global Vitamin Market Professional Survey Report 2016 Publication
SAMPLE. Asia-Pacific Drug Delivery Devices Market Outlook to Metered Dose Inhaler Devices, Infusion Systems, Central Venous
Asia-Pacific Drug Delivery Devices Market Outlook to 2018 - Metered Dose Inhaler Devices, Infusion Systems, Central Venous Catheters and Others Reference Code: GDME0220RDB Publication Date: January 2013
Information for Vermont Prescribers of Prescription Drugs
Information for Vermont Prescribers of Prescription Drugs CADUET (amlodipine besylate/atorvastatin calcium) tablets This list does not imply that the products on this chart are interchangeable or have
Medicines availability short-term supply issues Last updated 01/05/18
Short-term supply issues This resource includes availability information on medicines that are reported to have supply issues, with next expected availability within the next three months. This list is
Subsequent New Drugs Division. M/s.Troikaa. M/s. Olive Healthcare. Biological Division. M/s. Wockhardt Ltd. Global Clinical Trial Division
: The34 th SEC (Endocrinology & Metabolism) meeting held on 25.04.2017 at CDSCO HQ New Delhi and recommended the following: Age Subsequent New Drugs Division 1 12-146/2016-DC (Pt- Zim-Snd) Vitamin D3 (Cholecalciferol)
Information for Vermont Prescribers of Prescription Drugs
Information for Vermont Prescribers of Prescription Drugs LIPITOR (atorvastatin calcium) tablets This list does not imply that the products on this chart are interchangeable or have the same efficacy or
CHAPTER ONE: EXECUTIVE SUMMARY
CHAPTER ONE: EXECUTIVE SUMMARY Introduction Scope and Methodology Total Size and Growth of the Market Issues and Trends Affecting Market Leading Competitors CHAPTER TWO: INTRODUCTION AND INDUSTRY TRENDS
How and Why Vaccines Are Developed by Industry. Stanley A. Plotkin
How and Why Vaccines Are Developed by Industry Stanley A. Plotkin Merieux 2012 1 Why Vaccines are Different than Drugs 1) Given to healthy people, high safety required 2) Larger governmental role 3) Low
Exhibitor Prospectus
+ National Meeting and Expo 2018 Exhibitor Prospectus The 2018 Innovatix + Essensa National Meeting & Expo is the only event that provides access to Innovatix and Essensa s most engaged and active members,
SAMPLE. Syringes and Needles Market Outlook in BRICS (Brazil, Russia, India, China, South Africa) to Reference Code: GDME0166BDB
Syringes and Needles Market Outlook in BRICS (Brazil, Russia, India, China, South Africa) to 2018 Reference Code: GDME0166BDB Publication Date: January 2013 GlobalData. This report is a licensed product
Quality of medicines in Portugal: a retrospective review of medicine recalls ( ) Ana Teresa Reis Bruna Berardo Rui Loureiro
Quality of medicines in Portugal: a retrospective review of medicine recalls (2005-2015) Ana Teresa Reis Bruna Berardo Rui Loureiro Introduction Human medicines Cosmetics Veterinary medicines Medical devices
Nitrazepam. Nitrazepam Tablets TAJ GROUP PHARMACEUTICAL B U S I N E S S. Generics. Active Ingredients: Each tablet contains 10 mg Nitrazepam
Nitrazepam, Nitrazepam India, Nitrazepam manufacturers India, side effects Nitrazepam manufacturers, Taj Pharma India, Nitrazepam overdose, Nitrazepam drug, Nitrazepam composition, Manufacturing Pharmaceutical,
New Delhi, the 18 th December, 2017 ORDER
(Published in Part II, Section 3, Sub-section (ii) of the Gazette of India, Extraordinary) Government of India Ministry of Chemicals and Fertilizers Department of National Pharmaceutical Pricing Authority
Information for Vermont Prescribers of Prescription Drugs Long Form
Information for Vermont Prescribers of Prescription Drugs Long Form Pylera (bismuth subcitrate potassium, metronidazole, and tetracycline hydrochloride) Capsules The prices listed below are Average Wholesale
PHARMACEUTICALS EXPORT PROMOTION COUNCIL OF INDIA
Disbursement of MDA Claims to Individual Exporters during (-11) 1 JPN Pharma API China 80,000.00 2 Unique Biotech Limited Bio May 3-6, 80,000.00 3 Titan Biotech Limited Cphi Japan 21st to 23rd April 80,000.00
BOTANICAL AND PLANT-DERIVED DRUGS: GLOBAL MARKETS
BOTANICAL AND PLANT-DERIVED DRUGS: GLOBAL MARKETS BIO022G August 2015 Kim Lawson Project Analyst ISBN: 1-62296-134-X BCC Research 49 Walnut Park, Building 2 Wellesley, MA 02481 USA 866-285-7215 (toll-free
SickKids Research Institute: List of Funders
SickKids Research Institute: List of Funders 2009-2010 Agency Funding $ Agency Funding $ 3M Pharmaceuticals 2,901 International Council on Amino Acid Science 80,800 Abbott Diagnostics 6,639 International
M/s. Hetero Labs Ltd.
:- The 1 st SEC (Gastroenterology&Hepatology) meeting deliberated the proposals on 06.01.2017 and recommended the following:- Agenda New Drugs Division Proposal 1 12-54/16-DC Sofosbuvir and Velpatasvir
Companies Database, Mobile Database, Id Database, Credit
m All India Database We Provides Database Companies Database, Mobile Database, Email Id Database, Credit Card Holder Database, Corporate database, CEO s Database, Corporate Employee Database, Car s Owner
ORDER. Table. (1) (2) (3) (4) (5) (6) 1. Glimepiride Metformin Tablet
(Published in Part II, Section 3, Sub-section (ii) of the Gazette of India, Extraordinary) Government of India Ministry of Chemicals and Fertilizers Department of National Pharmaceutical Pricing Authority
Hyderabad, India Delegates. A comprehensive Bioanalysis conclave. April 27, Tentative program. Key notes SPONSORSHIP OPPORTUNITIES
INTERNATIONAL CONFERENCE & EXHIBITION Tentative program A comprehensive Bioanalysis conclave 7+ Key notes 50+ Poster presentations 100+ Delegates 2 + Panel Discussions April 27, 2018 Hyderabad, India SPONSORSHIP
WHO Global Price Reporting Mechanism the importance of data registration for the regulation of antiretrovirals (ARV) and access to treatment
WHO Global Price Reporting Mechanism the importance of data registration for the regulation of antiretrovirals (ARV) and access to treatment Boniface Dongmo Nguimfack HIV/Technology and Commodities 1 AMDS
Blood Glucose Test Strip Market Research Report- Global Forecast till 2020
Report Information More information from: https://www.marketresearchfuture.com/reports/976 Blood Glucose Test Strip Market Research Report- Global Forecast till 2020 Report / Search Code: MRFR/MED/0470-CRR
New Drugs Division. Frequently Asked Questions (FAQs) on Approval of new Phytopharmaceutical Drugs
Central Drugs Standard Control Organization Directorate General of Health Services Ministry of Health and Family Welfare Government of India New Drugs Division Frequently Asked Questions (FAQs) on Approval
List Of Antihepatitis Pharmaceutical Products (included to support Global Fund Policy for Co-Infections and Co-Morbidities)
Edition: Version 11-19th of July 2018 List of A & B Products List Of Antihepatitis Pharmaceutical Products (included to support Global Fund Policy for Co-Infections and Co-Morbidities) As from the version
Directorate General of Health Services Office of Drugs Controller General (India) (Biological Division)
Directorate General of Health Services Office of Drugs Controller General (India) (Biological Division) List of r-dna drug products approved in the country (Form 45 and 45A) from 1 st Jan 2015 to 30 th
CHAPTER THREE: INDUSTRY OVERVIEW... 6 STRUCTURE AND HISTORY OF THE DENTAL INDUSTRY... 6 STRUCTURE AND HISTORY (CONTINUED)... 8
CHAPTER ONE: INTRODUCTION... 1 STUDY GOALS AND OBJECTIVES... 1 REASONS FOR DOING THE STUDY... 1 SCOPE OF REPORT... 1 METHODOLOGY... 1 RELATED BCC STUDIES... 2 ANALYST CREDENTIALS... 2 BCC RESEARCH ONLINE
Global Coverage. Regional Coverage. Company Coverage. Country Coverage. Global Coverage Regional Coverage Country Coverage
Global Influenza Drugs and Vaccines Market By Drugs (Zanamivir, Oseltamivir Phosphate, Peramivir), By Vaccine (Trivalent, Quadrivalent): Analysis By Region, By Country: Opportunities and Forecast (2016-2021)
Excipient Regulations Perspective & Creation of IPEC India (Current Regulations & Emerging challenges for excipient regulations in India)
INTERNATIONAL PHARMACEUTICAL EXCIPIENTS COUNCIL OF INDIA (IPEC INDIA) Excipient Regulations Perspective & Creation of IPEC India (Current Regulations & Emerging challenges for excipient regulations in
TOTAL MAT 1,52,81, % Unit PTR (Rs.) MAT (Rs.) SKU wise MAT % प क व रण Pack Description छ प BRAND. क पन Company. S. No. Unique No.
Number of Companies consisting of Market Share of 1% & Above 2 3.1 Adrenaline Injection 1 mg/ml Per ml Sum of MAT value considered for price calculation (in Lakhs) 152.69 Sum of PTR per unit considered
THYROID HORMONE THERAPY TABLE 21 SHARES OF MANUFACTURERS/DISTRIBUTORS FOR FIGURE 4 SHARES OF MANUFACTURERS/DISTRIBUTORS FOR
CHAPTER ONE: INTRODUCTION... 1 STUDY GOALS AND OBJECTIVES... 1 REASONS FOR DOING THIS STUDY... 1 INTENDED AUDIENCE... 1 SCOPE OF REPORT... 2 METHODOLOGY... 2 INFORMATION SOURCES... 2 ANALYST S CREDENTIALS...
MEDICINES FOR SMOKING CESSATION: GLOBAL MARKETS. PHM154A September Anand Gijare Project Analyst ISBN:
MEDICINES FOR SMOKING CESSATION: GLOBAL MARKETS PHM154A September 2013 Anand Gijare Project Analyst ISBN: 1-56965-544-8 BCC Research 49 Walnut Park, Building 2 Wellesley, MA 02481 866-285-7215, 781-489-7301
Information for Vermont Prescribers of Prescription Drugs Tradjenta (linagliptin) and Jentadueto (linagliptin+metformin) Tablets
Information for Vermont Prescribers of Prescription Drugs Tradjenta (linagliptin) and Jentadueto (linagliptin+metformin) Tablets This list does not imply that the products on this chart are interchangeable
Sample Pages. Needlestick Safety Injection Devices Market, Copyright 2012 Banyan Wharf Consultants Ltd. Page 1
Sample Pages Needlestick Safety Injection Devices Market, 2014-2024 Copyright 2012 Banyan Wharf Consultants Ltd. Page 1 This page is intentionally left blank Copyright 2014 Roots Analysis Private Ltd.
Irritable Bowel Syndrome - Pipeline Review, H2 2016
Report Information More information from: https://www.wiseguyreports.com/reports/752817-irritable-bowel-syndrome-pipeline-review-h2-2016 Irritable Bowel Syndrome - Pipeline Review, H2 2016 Report / Search
Segment Coverage By Type By Age Group. Global Coverage Regional Coverage Country Coverage
Global Cervical Cancer Diagnostics Market By Type (Pap Testing, HPV Testing, Colposcopy and Cervical Biopsies), By Age Group (35 years): Forecast to 2022 By Type - Pap Test, HPV Test,
Free Trial Future Generics Database
API Atazanavir Structure O 2 C N H O H N OH N NH O N H N CO2 Brand REYATAZ (BMS : World) Indication Antiviral Originator Ciba-Geigy (Novartis) Developer / Licensee BMS Comments Atazanavir is an azapeptide
OVER-THE-COUNTER (OTC) DRUGS AND DIETARY SUPPLEMENTS: GLOBAL MARKETS
OVER-THE-COUNTER (OTC) DRUGS AND DIETARY SUPPLEMENTS: GLOBAL MARKETS PHM050B February 2014 Anand Gijare Project Analyst ISBN: 1-56965-690-8 BCC Research 49 Walnut Park, Building 2 Wellesley, MA 02481 USA
NATIONAL INSTITUTE FOR HEALTH AND CARE EXCELLENCE GUIDANCE EXECUTIVE (GE) Consideration of consultation responses on review proposal
NATIONAL INSTITUTE FOR HEALTH AND CARE EXCELLENCE GUIDANCE EXECUTIVE (GE) Consideration of consultation responses on review proposal Review of TA215; Pazopanib for the first line treatment of advanced
THERAPIES AND BIOMARKERS FOR INFLAMMATORY BOWEL DISEASE
THERAPIES AND BIOMARKERS FOR INFLAMMATORY BOWEL DISEASE PHM125A January 2013 Willem Westra Project Analyst ISBN: 0-89336-715-X BCC Research 49 Walnut Park, Building 2 Wellesley, MA 02481 866-285-7215,
1. Dr. Shyam Agarwal, Joint Secretary, Department of Commerce. 2. Shri A.K. Bamba, Director, Department of Commerce
Minutes of Meeting of Inter Ministerial Committee (IMC) for consideration of proposals for setting up ICDs / CFSs held under Chairmanship of Shri P.K. Chaudhery, Additional Secretary (AS), Department of
Vascular Endothelial Growth Factor Inhibitor Market
May 2017 Report Id : REP-GB-3292 Status : Ongoing Category : Healthcare, Pharmaceuticals & Medical Devices 2015 Future Market Insights, All Rights Reserved About Future Market Insights Future Market Insights
CHAPTER ONE: EXECUTIVE SUMMARY
CHAPTER ONE: EXECUTIVE SUMMARY Introduction Scope and Methodology Size and Growth of the Market Issues and trends Leading Competitors CHAPTER TWO: INTRODUCTION AND OVERVIEW Definition of Pain Magnitude
TABLE 7 ADVANTAGES AND DISADVANTAGES OF TOXOID VACCINES SUBUNIT VACCINES Applications of Subunit Vaccines TABLE 8 APPLICATIONS OF
CHAPTER ONE: INTRODUCTION... 1 STUDY OBJECTIVES... 1 REASONS FOR DOING THIS STUDY... 1 INTENDED AUDIENCE... 2 SCOPE OF THE STUDY... 2 METHODOLOGY... 2 INFORMATION SOURCES... 2 ABOUT THE AUTHOR... 3 RELATED
Information for Vermont Prescribers of Prescription Drugs Long Form Fetzima (levomilnacipran) Extended Release Capsules
Information for Vermont Prescribers of Prescription Drugs Long Form Fetzima (levomilnacipran) Extended Release Capsules The prices listed below are Average Wholesale Prices ( AWP ) as established and made
Irritable Bowel Syndrome - Pipeline Review, H2 2016
Published on Market Research Reports Inc. (https://www.marketresearchreports.com) Home > Irritable Bowel Syndrome - Pipeline Review, H2 2016 Irritable Bowel Syndrome - Pipeline Review, H2 2016 Publication